Clinical trial · Interventional
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
CD34+Stem Cell Selection for Patients Receiving Partially Matched Family or Matched Unrelated Adult Donor Allogeneic Stem Cell Transplantations for Malignant and Non-Malignant Disease
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
CD34+ stem cell selection in children, adolescents and young adults receiving partially matched family donor or matched unrelated adult donor allogeneic bone marrow or peripheral blood stem cell transplant will be safe and well tolerated and be associated with a low incidence of serious (Grade III/IV) acute and chronic graft versus host disease (GVHD).
Conditions
Conditions (8)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Beta Thalassemia | — | UNRESOLVED | — |
| Bone Marrow Failure | — | UNRESOLVED | — |
| Histiocytosis | — | UNRESOLVED | — |
| Immunodeficiencies | — | UNRESOLVED | — |
| Inborn Errors of Metabolism | — | UNRESOLVED | — |
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Sickle Cell Disease | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Full Intensity | Drug | — | UNRESOLVED |
| Full Intensity with TBI | Drug | — | UNRESOLVED |
| Reduced Intensity | Drug | — | UNRESOLVED |
| Reduced Intensity (Fanconi) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Thiotepa/Cyclophosphamide/ATG
- description
- Full intensity with TBI
- interventionNames
- Drug: Full Intensity with TBI
- type
- EXPERIMENTAL
- label
- Busulfan/Melphalan/ATG
- description
- Full intensity without TBI
- interventionNames
- Drug: Full Intensity
- type
- EXPERIMENTAL
- label
- Busulfan/Fludarabine/Alemtuzumab
- description
- Reduced Intensity Chemotherapy
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Adequate renal function defined as:Serum creatinine \<1.5 x normal, or Creatinine clearance or radioisotope GFR \>60 ml/min/m2 or an equivalent GFR as determined by the institutional normal range. * Adequate liver function defined as:Total bilirubin \<1.5 x normal, or SGOT (AST) or SGPT (ALT) \<3.0 x normal * Adequate cardiac function defined as:Shortening fraction \>27% by echocardiogram, or Ejection fraction of \>47% by radionucleotide angiogram or echocardiogram. * Adequate pulmonary function defined as:Uncorrected DLCO \>50% by pulmonary function test. For children who are uncooperative, no evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry \>94% on room air. Eligibility for Reduced Intensity Regimen: * Adequate renal function defined as:Serum creatinine 2.0 x normal, or creatinine clearance or radioisotope GFR \> 40 ml/min/m2 or an equivalent GFR as determined by the institutional normal range. * Adequate liver function defined as:Total bilirubin \< 2.5 x normal; or SGOT (AST) or SGPT (ALT) \< 5.0 x normal. * Adequate cardiac function defined as:Shortening fraction of \>25% by echocardiogram, or Ejection fraction of \>40% by radionuclide angiogram or echocardiogram. * Adequate pulmonary function defined as:DLCO \>35% by pulmonary function test. For children who are uncooperative, no evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry \>94% in room air. Exclusion Criteria: * Pregnancy/Breast Feeding: Females who are pregnant or breast-feeding are not eligible. * Infection: Patients with documented uncontrolled infection at the time of study entry are not eligible.
References
Publications (0)
Data not yet available